Onkologie. 2015:9(5):218-220

Comprehensive treatment of pituitary adenomas

Karel Máca, Václav Vybíhal, Martin Smrčka
Neurochirurgická klinika LF Masarykovy univerzity Brno a FN Brno

Pituitary tumours constitute 10–15 % of all intracranial tumours. Adenomas are the most common and account for 80 % of tumours of

the sella turcica. Their incidence is 1.5–2/100,000 / year and prevalence 20/100 000. The vast majority of adenomas have a benign course.

Comprehensive treatment of pituitary adenomas requires cooperation among a neurosurgeon, an endocrinologist, a radiosurgeon,

a radiologist and an ophthalmologist. The main treatment modality with the exception of prolactinomas is surgery. Using of new neurosurgical

techniques have permitted to increase the extent of surgery without increasing the risk to the patient. The goal of treatment

is such an influence on the tumour that does not preclude the patient to live a normal life without the need for hormone replacement

and without affecting vision.

Keywords: pituitary adenoma, treatment of pituitary adenoma, pituitary surgery

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Máca K, Vybíhal V, Smrčka M. Comprehensive treatment of pituitary adenomas. Onkologie. 2015;9(5):218-220.
Download citation

References

  1. DeLellis RA, Lloyd RV, Hertz PU, Eng Ch. Tumours of Endocrine Organs, Pathology and Genetics, Lyon, IARC Press, 2003.
  2. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML et al. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101(3): 613-619. Go to original source...
  3. Česák T, Náhlovský J, Hosszú T, Řehák S, Látr I, Němeček S, Čáp J, Ryška P, Šuba P, Cerman J. Longitudinální sledování růstu po operačních reziduí afunkčních adenomů hypofýzy. Cesk Slov Neurol N 2009; 72/105(2): 115-124.
  4. Oyama K, Sanno N, Tahara S, Teramoto A. Management of pituitary incidentalomas: according to survey of pituitary incidentalomas in Japan. Semin Ultrasound CT MR 2005; 26(1): 47-50. Go to original source...
  5. Netuka D, Masopust V, Benš V. Léčba adenomů hypofýzy, Cesk Slov Neurol N 2011; 74/107(3): 240-253.
  6. Lindholm J. A century of pitiutary surgery: Schloffers legacy. Neurosurgery 2007: 61(4): 865-867. Go to original source... Go to PubMed...
  7. Cushing H. The Weir Mitchell Lecture: Surgical experiences with pituitary disorders. Jour A M A 63:1515-1525, 1914. Go to original source...
  8. Jho HD: Endoscopic transsphenoidal surgery. J Neurooncol 2001; 54: 187-195. Go to original source...
  9. Jho HD, Ha HG. Endoscopic endonasal skull base surgery: Part 1-The midline anterior fossa skull base. Minim Invasive Neurosurg 2004; 47: 1-8. Go to original source... Go to PubMed...
  10. Jho HD, Ha HG. Endoscopic endonasal skull base surgery: Part 2-The cavernous sinus. Minim Invasive Neurosurg 2004; 47: 9-15. Go to original source... Go to PubMed...
  11. Jho HD, Ha HG. Endoscopic endonasal skull base surgery: Part 3-The clivus and posterior fossa. Minim Invasive Neurosurg 2004; 47: 16-23. Go to original source... Go to PubMed...
  12. Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: Experience with 50 patients. J Neurosurg 1997; 87: 44-51. Go to original source... Go to PubMed...
  13. Jho HD, Carrau RL. Endoscopy assisted transsphenoidal surgery for pituitary adenoma. Technical note. Acta Neurochir (Wien) 1996; 138: 1416-1425. Go to original source... Go to PubMed...
  14. Cappabianca P, Alfieri A, de Divitiis E. Endoscopic endonasal transsphenoidal approach to the sella: Towards functional endoscopic pituitary surgery (FEPS). Minim Invasive Neurosurg 1998; 41: 66-73. Go to original source... Go to PubMed...
  15. Cappabianca P, Cavallo LM, Colao A, de Divitiis E. Surgical complicationsassociated with the endoscopic endonasal transsphenoidal approach for pituitaryadenomas. J Neurosurg 2002; 97: 293-298. Go to original source... Go to PubMed...
  16. Cappabianca P, Cavallo LM, Mariniello G, de Divitiis E. Easy sellar reconstruction in endoscopic endonasal transsphenoidal surgery with polyester-silicone dural substitute and fibrin glue: technical note. Neurosurgery 2001; 49(2): 473-476. Go to original source... Go to PubMed...
  17. Cappabianca P, Cavallo LM, Colao A, Del Basso De Caro M, Esposito F, Cirillo S, Lombardi G, de Divitiis E. Endoscopic endonasal transsphenoidal approach: Outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg 2002; 45: 193-200. Go to original source... Go to PubMed...
  18. Cappabianca P, Frank G, Pasquini E, Divitiis O, Calbucci F. Extended endoscopic endonasal transsphenoidal approaches to the suprasellar region, planum sphenoidale and clivus, in Cappabianca P, de Divitiis E (eds): Endoscopic Endonasal Transsphenoidal Surgery.Wien, Springer-Verlag, 2003: 176-187. Go to original source...
  19. de Divitiis E, Esposito F, Cappabianca P, Cavallo LM, de Divitiis O. Tubercullum sellae meningiomas: high route or low route? A series of 51 consecutive cases. Neurosurgery 62(3): 2008; 556-563. Go to original source... Go to PubMed...
  20. de Divitiis E, Cappabianca P, Cavallo LM, Esposito F, de Divitiis O, Messina A. Extended endoscopic transsphenoidal approach for extrasellar craniopharyngiomas. Neurosurgery 2007; 61(5 Suppl 2): 219-227. Go to original source... Go to PubMed...
  21. de Divitiis E, Cavallo M. Endoscopic Endonasal Transsphenoidal Approach to the Sellar Region. Wien, Springer, 2003. Go to original source...
  22. de Divitiis E, Cavallo LM, Cappabianca P, Esposito F. Extended endoscopic endonasal transsphenoidal approach for the removal of suprasellar tumors: Part 2. Neurosurgery 2007; 60: 46-59. Go to original source... Go to PubMed...
  23. Sheehan JP, Niranjan A, Sheehan JM. Sterotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical armamentarium. J Neurosurg 2005; 102(4): 678-691. Go to original source... Go to PubMed...
  24. Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005; 8(1): 3-6. Go to original source... Go to PubMed...
  25. Colao A, Di Sarno A, Sarnacchiaro S. Prolactinomas resistant to standard dopamine agonists to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 82(3): 876-873. Go to original source... Go to PubMed...
  26. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999; 2(1): 29-41. Go to original source... Go to PubMed...
  27. Trainer PJ, Drake WM, Katznelson L. Treatment of acromegaly with growth hormone-receptor antagonist pegvisomant. N Eng J Med 2000; 342(16): 1171-1177. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.